Sunday, 22 July 2018 - 13:50
  • it
  • de
  • en
  • fr

Type 2 diabetes

Diabetes and macular edema: winning strategy

Prevention and innovative treatments for the best patient management The diseases that can impair sight create great concern, but for people with diabetes the threat is even more critical. This is due to the fact that in case of low…

Novo Nordisk’s Ozempic approved also in Europe

Denmark-based Novo Nordisk yesterday announced that the European Commission has approved Ozempic (semaglutide) for the treatment of type-2 diabetes as a once-weekly treatment in a Multi-Dose Pen. Novo Nordisk expects to launch Ozempic in Europe in H2 2018. Ozempic has…

Review, adherence to treatment in type 2 diabetes

A systematic review of observational and interventional studies investigating adherence to treatment in patients with type 2 diabetes treated with hypoglicemizing agents has been published in the journal Diabetes, Obesity and Metabolism. Researchers from Surrey University, after assessing data from…

Coffee consumption: more benefits than risks

A research investigating the safety of everyday coffee drinking has been published in the The British Medical Journal. The researchers have analyzed over 200 studies and have concluded that drinking two or three cups per day – that is 400mg…

Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER…

Revolutionary study on type-2 diabetes and its transmissibility

A team of scientists led by Claudio Soto, from McGovern Medical School (University of Texas Health Science Center at Houston) has published an interesting article in the review Experimental Medicine, reporting the results from a study aimed at demonstrating that…

Novo’s Victoza, positive opinion by FDA EMDAC on cardiovascular outcomes

Novo Nordisk announced that FDA EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) discussed the sNDA (supplemental New Drug Application) submitted by the company in order to have data on cardiovascular outcomes from the LEADER trial included in Victoza’s label (liraglutide)….

GLP-1 in complex with a protein: can monthly doses be reduced?

A new study conducted in animal models demonstrated that it is possible to increase the half-life of a class of antidiabetic drugs called GLP-1 by modifying their molecule. Indeed, such drugs showed efficacy in glycaemia monitoring in diabetes patients, yet…

Diabetes, Sanofi’s Soliqua 100/33 now available in the US

Sanofi announced that Soliqua™ (glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is available in the US starting from today. The product is intended for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide….

Novo Nordisk applies to FDA and EMA for approval of semaglutide

Novo Nordisk announced it submitted a NDA (New Drug Application) to the FDA and a MAA (Marketing Authorisation Application) to the EMA for semaglutide, a new GLP-1 analogue to be administered only once-weekly. The product is intended for the treatment…